

Exhibit B

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

IN RE: PHARMACEUTICAL)
INDUSTRY AVERAGE)
WHOLESALE PRICE LITIGATION)
_____)

MDL No. 1456
Master File No. 1:01-CV-12257-PBS
Sub-Category Case No. 1:08-CV-11200

THIS DOCUMENT RELATES TO:)
United States ex rel. Ven-A-Care of the)
Florida Keys, Inc. v. Baxter Healthcare)
Corporation)
_____)
Case No. 10-cv-11186-PBS)

Judge Patti B. Saris

DECLARATION OF HEIDI M. SMITH

I, Heidi M. Smith, declare and state as follows:

1. I am a paralegal supervisor for the law firm Goldberg Kohn Ltd. ("Goldberg Kohn"), one of the law firms representing Relators Linnette Sun and Greg Hamilton ("Relators") in *United States ex rel. Sun and Hamilton v. Baxter Healthcare Corporation, et al.*, Case No. 08-cv-11200-PBS (the "*Sun/Hamilton*" case). I have been employed by Goldberg Kohn since 2004.

2. At the direction of the attorneys at Goldberg Kohn, I accessed certain information regarding amounts spent by various state Medicaid Programs for reimbursement of the cost of filling prescriptions for the drug known as "Advate," and imported that information into an Excel spreadsheet. The results of that work are attached hereto as Exhibit 1. I have personal knowledge of the matters set forth herein and could testify competently thereto if called as a witness.

3. The information I accessed to prepare Exhibit 1 is contained on a publicly available website – www.medicaid.gov ("Medicaid website"). I have no independent information about the validity or accuracy of the information contained on the Medicaid website. Instead, I simply imported the information from the Medicaid website into an Excel spreadsheet in the manner described in this Declaration.

4. The Medicaid website indicates that it contains information regarding, "the active drugs that have been reported by participating drug manufacturers as of the most recent rebate reporting period under the Medicaid Drug Rebate Program. All drugs are identified by National Drug Code (NDC), unit type, units per package size, product name . . .," etc. (See, Exhibit 2, attached hereto, or visit the Medicaid website at: <http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program-Data.html>.)

5. The Medicaid website also purportedly provides "State Utilization Data" "for covered outpatient drugs paid for by State Medicaid agencies since the start of the Medicaid Drug Rebate Program." (*Id.*) This data purports to be provided quarterly for each participating State, as well as nationally. (*Id.*)

6. At the time I was asked to access the information on the Medicaid website, the data set forth in paragraphs 4 and 5, above, was organized by year, and contained within .zip files that could be downloaded ("Utilization .zip file"). Each Utilization .zip file contained approximately 50 unformatted text files containing individual State data – for instance, "ILUTIL07.txt" contained the 2007 utilization data for the State of Illinois – and one unformatted text file that combined all reported state data into a single text file containing the

national data – for instance, "NAUTIL07.txt" contained a compilation of the data reported by each of the participating States for 2007.¹ The unformatted nature of these files allows the data to be imported into various computer programs, including Microsoft Excel – the program into which I imported the data and used to create Exhibit 1.

7. The Medicaid website also provided "Web File Structure and Definitions" to be used in understanding the data contained within the unformatted text files of the Utilization .zip files. According to this document, the following data was contained within the unformatted text files: "State Code," "Labeler Code," "Product Code," "Package Size," "Period Covered," "Product FDA List Name," "Units Reimbursed," "No. of Prescriptions," "Total Amount Reimbursed," "Medicaid Amount Reimbursed," and "Non-Medicaid Amount Reimbursed." A copy of this document, available at the time I accessed the information, is attached hereto as Exhibit 3. This document is also available on the Medicaid website at: http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program-Data.html\State_drug_utilization_data_specifications.pdf.

8. For purposes of creating the spreadsheet attached as Exhibit 1, I used the text files containing the national data, which were a compilation of the data reported by each of the participating States. The steps I used to import the national data into Exhibit 1 are set forth below.

¹ Since the time I prepared Exhibit 1, the Medicaid website has been modified so that the data is no longer available in a single .zip file. The website is now formatted to provide access to each file individually.

ADVATE MEDICAID REIMBURSEMENT: 2003 TO 3rd QUARTER 2011

9. I accessed the Utilization .zip files for 2003 through the third quarter ("Q3") of 2011 (the most current data available at the time I prepared Exhibit 1), and then extracted the text files containing the national data for each year.

10. Next, I extracted the reported data for *only* the Advate products (i.e. the rows in the files where the word "Advate" appeared in the column corresponding to "Product FDA List Name") from each of the text files containing the national data for 2003 through Q3 2011. An example of one such file is attached hereto as Exhibit 4.

11. I then imported the extracted national Advate data for 2003 through Q3 2011 into an Excel spreadsheet, creating separate worksheets for each year. (See, Exhibit 1.)

12. The national Advate product data I imported is reflected on the worksheets in Exhibit 1 as follows:

COLUMN	DATA FROM TEXT FILE (as Identified on Exhibit 3)
A	"State Code" (for national data "XX" converted to "US")
B	"Labeler Code"
C	"Product Code"
D	"Package Size"
E	"Period Covered (By Quarter)"
F	"Product FDA List Name"
G	"Units Reimbursed"
H	"No. of Prescriptions"
I	"Total Amount Reimbursed" ²
J	"Medicaid Amount Reimbursed"
K	"Non-Medicaid Amount Reimbursed"

² Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." (See, Exhibit 2 or visit the Medicaid website at: <http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program-Data.html>.) Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. (*Id.*) For purposes of preparing Exhibit 1, "Total Amount Reimbursed" was used for 2004 through 2007, and "Medicaid Amount Reimbursed" was used for 2008 through Q3 2011.

13. In order to include the reimbursement paid per unit ("RPI") in Exhibit 1, I added a column (L) titled "Reimbursement/Unit" to each worksheet and inserted a formula for each line of reported data which divided the "Total Amount Reimbursed" (column I) – or "Medicaid Amount Reimbursed (column J) for years 2008 to Q3 2011 (see footnote 2) – by the "Units Reimbursed" (column G) to arrive at the RPI reimbursed by Medicaid on a national level for each listed Advate product.

14. Next, I added a column (M) to each worksheet to reflect the Pharmacy Acquisition Cost ("PAC") which is not available on the Medicaid website. The specific numbers that appear in the PAC column were provided to me by counsel for the Relators, and it is my understanding these numbers came from Relator Greg Hamilton.

15. Finally, I added a column (N) to each worksheet titled "Amount Medicaid Paid in Excess of PAC," and inserted a formula which first subtracted PAC (column M) from RPI (column L) to arrive at the *per unit* amount Medicaid paid in excess of PAC, and then multiplied that number by the reported number of "Units Reimbursed" (column G) to arrive at the *total* amount Medicaid paid in excess of PAC for each Advate product.

**REDUCTIONS FOR SETTLEMENTS WITH STATES OF
CALIFORNIA, HAWAII, ILLINOIS, NEVADA AND TEXAS**

16. I also performed a series of calculations to adjust the totals identified in paragraph 15, above, using the payments in excess of PAC made by the states of California, Hawaii, Illinois, Nevada and Texas (collectively, "Settling States") during the following time periods:

SETTLING STATE	TIME PERIOD
California	2003 – 2008
Hawaii	2003 – Q1 2009
Illinois	2003 – Q1 2009
Nevada	2003 – Q3 2008
Texas	2003 – Q2 2006

17. The time periods for which adjustments were made for the Settling States were provided to me by counsel for the Relators.

18. To determine the amount by which a quarter and/or year should be adjusted, I followed the same procedures set forth in paragraphs 9 through 12 above, this time extracting the unformatted text files for each of the Settling States from the Utilization .zip files and importing the reported data for the Advate products only.

19. I calculated the amount Medicaid paid in excess of PAC for each of the Settling States, during the time periods set forth in paragraph 16, above, in the same manner as set forth in paragraphs 13 through 15, above.

20. Next, I inserted a formula in column N, beneath the totals set forth in paragraph 15, above, that subtracted the amount Medicaid paid in excess of PAC for each Settling State, for the time periods set forth in paragraph 16 above, from the national totals as described in paragraph 15, above, to arrive at the adjusted amounts.

21. The adjustments for the Settling States reduced the national totals for the time periods set forth in paragraph 16, above, are reflected in the "Amount Medicaid Paid in Excess of PAC" (column N) of the relevant worksheets of Exhibit 1.


PROJECTION FOR Q4 2011

22. At the time I performed the calculations set forth above, utilization data was not available on the Medicaid website for Q4 2011.

23. The total amount Medicaid paid in excess of PAC for Q4 2011 was estimated by calculating the average of the total amounts Medicaid paid in excess of PAC for Q1 2011 through Q3 2011. That average was added to the amounts Medicaid paid in excess of PAC for Q1 2011 through Q3 2011 to arrive at an estimate for the total amount Medicaid paid in excess of PAC for 2011. These amounts are reflected in column N, rows 31 and 32, of the 2011 worksheet of Exhibit 1.

24. Under 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Executed on this 12th day of November 2012.



Heidi M. Smith

Exhibit 1

SUMMARY SHEET**Amounts Medicaid Paid in Excess of Pharmacy Acquisition Cost ("PAC") 2003 to 2011**

Year	Amount
2003	\$1,086,865.77
2004	\$9,949,858.22
2005	\$13,861,813.01
2006	\$19,746,719.87
2007	\$17,761,835.57
2008	\$19,598,476.81
2009	\$26,755,721.57
2010	\$32,730,272.37
2011	\$29,250,045.20 ¹
TOTAL (after adjustments for Settling States)	\$170,741,608.38 ²

¹ The total amount Medicaid paid in excess of PAC for Q4 2011 was estimated by calculating the average of the total amounts Medicaid paid in excess of PAC for Q1 2011 through Q3 2011. That average was added to the amounts Medicaid paid in excess of PAC for Q1 2011 through Q3 2011 to arrive at an estimate for the total amount Medicaid paid in excess of PAC for 2011.

² The total amount Medicaid paid in excess of PAC, based on national data, was reduced using data reported by the Settling States of California, Hawaii, Illinois, Nevada and Texas. Reductions were applied for the following time periods: California - 2003 - 2008; Hawaii - 2003 - Q1 2009; Illinois - 2003 - Q1 2009; Nevada - 2003 - Q3 2008; and Texas - 2003 - Q2 2006.

2011 (Q1 - Q3)

A	B	C	D	E	F	G	H	I	J	K	L	M	N
STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED	MEDICAID AMOUNT REIMBURSED	NON-MEDICAID AMOUNT REIMBURSED	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1	US	2940	1	2011 Q1	ADVATE 250	31,226.00	8.00	33695.03	33695.03	0	\$1.08	\$0.93	\$4,654.85
2	US	2940	1	2011 Q2	ADVATE 250	28,651.00	10.00	23337.16	23337.16	0	\$0.81	\$0.93	\$3,306.27
3	US	2940	1	2011 Q3	ADVATE	1,958.00	1.00	1203.7	1203.7	0	\$0.61	\$0.93	\$617.24
4	US	2940	2	2011 Q1	ADVATE 500	10,089.00	5.00	12606.08	12606.08	0	\$1.25	\$0.93	\$3,214.01
5	US	2940	2	2011 Q2	ADVATE 500	53,816.00	23.00	40537.78	40537.78	0	\$0.61	\$0.93	\$9,511.10
6	US	2940	2	2011 Q3	ADVATE	11,880.00	4.00	7303.35	7303.35	0	\$0.61	\$0.93	\$3,745.05
7	US	2940	2	2011 Q1	ADVATE 1.0	3,090.00	1.00	3423.41	3423.41	0	\$1.11	\$0.93	\$549.71
8	US	2940	3	2011 Q2	ADVATE 1.0	2,082.00	2.00	2358.49	2358.49	0	\$1.13	\$0.93	\$422.23
9	US	2940	4	2011 Q3	ADVATE	487.00	1.00	308.17	308.17	0	\$0.62	\$0.93	\$153.04
10	US	2940	10	2011 Q1	ADVATE 200	1,238,039.00	363.00	138378.77	1384976.94	18901.83	\$1.11	\$0.93	\$213,600.67
11	US	2941	10	2011 Q2	ADVATE 200	1,688,107.10	462.00	197566.55	1872547.29	103319.26	\$1.11	\$0.93	\$302,607.69
12	US	2941	10	2011 Q3	ADVATE 200	1,322,347.00	344.00	1524579.47	1516578.41	8001.06	\$1.15	\$0.93	\$286,785.70
13	US	2941	10	2011 Q1	ADVATE 201	4,377,524.00	631.00	4995147.39	4904170.61	90976.78	\$1.12	\$0.93	\$833,073.29
14	US	2942	10	2011 Q2	ADVATE 401	4,744,240.40	716.00	5877312.85	5378230.64	489092.21	\$1.13	\$0.93	\$966,087.07
15	US	2942	10	2011 Q3	ADVATE 401	3,033,957.39	466.00	3541034.01	3446339.18	94694.83	\$1.14	\$0.93	\$624,758.81
16	US	2943	10	2011 Q1	ADVATE 801	5,164,024.00	434.00	6031949.89	5986313.3	45366.58	\$1.16	\$0.93	\$1,183,770.98
17	US	2943	10	2011 Q2	ADVATE 801	5,598,815.80	491.00	6814156.55	6471240.02	342916.53	\$1.16	\$0.93	\$1,254,341.33
18	US	2943	10	2011 Q3	ADVATE 801	5,302,622.50	433.00	6183196.25	5882979.55	300216.7	\$1.11	\$0.93	\$951,540.63
19	US	2944	10	2011 Q1	ADVATE 1.2	7,295,962.00	391.00	8298474.33	8044873.03	253901.3	\$1.10	\$0.93	\$1,259,628.37
20	US	2944	10	2011 Q2	ADVATE 1.2	7,985,224.00	429.00	9014218.92	8788615.3	225404.62	\$1.10	\$0.93	\$1,362,556.98
21	US	2944	10	2011 Q3	ADVATE 1.2	5,106,373.60	289.00	566619.16	5495722.78	171096.38	\$1.08	\$0.93	\$746,785.33
22	US	2945	10	2011 Q1	ADVATE 1.8	11,786,688.20	455.00	13381365.88	12842008.61	539357.38	\$1.09	\$0.93	\$1,880,388.58
23	US	2945	10	2011 Q2	ADVATE 1.8	13,310,378.80	550.00	15684848.48	14140702.92	1544145.57	\$1.06	\$0.93	\$1,752,050.61
24	US	2945	10	2011 Q3	ADVATE 1.8	10,140,756.10	433.00	11834885.47	10794984.72	1039900.75	\$1.06	\$0.93	\$1,394,891.55
25	US	2946	10	2011 Q1	ADVATE 2.4	16,115,530.20	440.00	18163989.68	17328337.78	836671.91	\$1.08	\$0.93	\$2,340,884.69
26	US	2946	10	2011 Q2	ADVATE 2.4	19,818,015.80	600.00	2306706.13	20651296.66	2415408.47	\$1.05	\$0.93	\$2,405,611.87
27	US	2946	10	2011 Q3	ADVATE 2.4	14,560,858.10	431.00	16378599.31	15739052.59	639546.72	\$1.08	\$0.93	\$2,197,453.63
28	US	2946	10	2011 Q1	ADVATE 2.4								
29	US	2946	10	2011 Q2	ADVATE 2.4								
30	US	2946	10	2011 Q3	ADVATE 2.4								
31	US	2946	10	2011 Q1	ADVATE 2.4								
32	US	2946	10	2011 Q2	ADVATE 2.4								
33	US	2946	10	2011 Q3	ADVATE 2.4								
34	US	2946	10	2011 Q1	ADVATE 2.4								
35	US	2946	10	2011 Q2	ADVATE 2.4								
36	US	2946	10	2011 Q3	ADVATE 2.4								
37	US	2946	10	2011 Q1	ADVATE 2.4								
TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC FOR 2011:													\$29,250,045.20
Q1 - Q3 actual													\$21,937,533.90
Q4 projected													\$7,312,511.30
Total Q1-Q4													\$28,250,045.20

**TOTAL AMOUNT MEDICAID REIMBURSED IN
EXCESS OF PAC FOR 2010:**

2009 (Q1-Q4)

A	B	C	D	E	F	G	H	I	J	K	L	M	N
STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED	MEDICAID AMOUNT REIMBURSED	NON-MEDICAID AMOUNT REIMBURSED	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1	944	2940	1	2009 Q1	ADVATE ANT	260.00	1	\$263.50	\$263.50	\$0.00	\$1.01	\$0.93	\$21.70
2	944	2940	1	2009 Q2	ADVATE ANT	1,016.00	1	\$1,124.35	\$1,124.35	\$0.00	\$1.11	\$0.93	\$179.47
3	944	2940	1	2009 Q3	ADVATE 250	7,083.00	3	\$8,288.79	\$8,288.79	\$0.00	\$1.17	\$0.93	\$1,701.60
4	944	2940	1	2009 Q4	ADVATE 250	2,009.00	4	\$1,661.34	\$1,661.34	\$0.00	\$0.83	\$0.93	\$207.03
5	944	2940	2	2009 Q1	ADVATE 500	14,199.00	3	\$19,195.14	\$19,195.14	\$0.00	\$1.35	\$0.93	\$5,990.07
6	944	2940	2	2009 Q2	ADVATE ANT	12,342.00	5	\$47,352.05	\$47,352.05	\$0.00	\$3.84	\$0.93	\$35,873.99
7	944	2940	2	2009 Q3	ADVATE 500	27,248.00	11	\$44,622.76	\$44,622.76	\$0.00	\$1.64	\$0.93	\$19,282.12
8	944	2940	2	2009 Q4	ADVATE 500	20,239.00	8	\$16,915.75	\$16,915.75	\$0.00	\$0.94	\$0.93	\$1,906.52
9	944	2940	3	2009 Q1	ADVATE 1.0	77,253.00	8	\$56,529.08	\$56,529.08	\$38,923.20	\$0.73	\$0.93	\$15,239.41
10	944	2940	3	2009 Q2	ADVATE 1.0	162,403.00	24	\$389,055.05	\$175,545.02	\$213,510.03	\$1.08	\$0.93	\$24,510.23
11	944	2940	3	2009 Q3	ADVATE 1.0	62,506.00	19	\$107,059.48	\$107,059.48	\$71,056.66	\$1.16	\$0.93	\$48,928.80
12	944	2940	3	2009 Q4	ADVATE ANT	98,148.00	18	\$114,194.17	\$114,194.17	\$3,190.32	\$1.16	\$0.93	\$22,916.53
13	944	2940	4	2009 Q1	ADVATE ANT	57,302.00	4	\$117,384.49	\$85,172.83	\$77,430.96	\$1.49	\$0.93	\$31,881.97
14	944	2940	4	2009 Q2	ADVATE 1.5	71,973.00	9	\$223,108.88	\$187,191.67	\$35,915.21	\$2.60	\$0.93	\$120,256.78
15	944	2940	4	2009 Q3	ADVATE 1.5	60,750.00	7	\$57,712.50	\$57,712.50	\$0.00	\$0.95	\$0.93	\$1,215.00
16	944	2940	4	2009 Q4	ADVATE ANT	13,345.00	3	\$14,921.44	\$14,921.44	\$0.00	\$1.12	\$0.93	\$2,510.59
17	944	2940	10	2009 Q1	ADVATE ANT	26,460.00	1	\$28,673.80	\$5,712.36	\$22,861.44	\$0.22	\$0.93	\$18,895.44
18	944	2940	10	2009 Q2	ADVATE ANT	22,680.00	1	\$24,491.40	\$4,895.88	\$19,595.52	\$0.22	\$0.93	\$16,196.52
19	944	2940	10	2009 Q3	ADVATE 200	873,898.00	231	\$1,037,607.96	\$1,026,982.82	\$10,625.14	\$1.18	\$0.93	\$214,257.68
20	944	2941	10	2009 Q4	ADVATE 200	1,126,099.00	329	\$1,289,624.56	\$1,286,109.06	\$3,715.50	\$1.14	\$0.93	\$238,836.99
21	944	2941	10	2009 Q1	ADVATE 200	906,514.00	296	\$1,109,344.29	\$1,086,347.70	\$22,996.59	\$1.20	\$0.93	\$248,538.89
22	944	2941	10	2009 Q2	ADVATE 200	1,056,065.00	288	\$1,249,108.97	\$1,230,679.44	\$18,429.53	\$1.17	\$0.93	\$248,538.89
23	944	2942	10	2009 Q3	ADVATE 401	3,268,823.00	429	\$3,923,121.91	\$3,882,663.64	\$40,458.27	\$1.19	\$0.93	\$942,658.25
24	944	2942	10	2009 Q4	ADVATE 401	3,604,938.00	510	\$4,204,112.58	\$4,168,443.22	\$35,669.36	\$1.16	\$0.93	\$915,850.88
25	944	2942	10	2009 Q1	ADVATE 401	2,978,993.00	412	\$3,461,185.96	\$3,347,951.54	\$113,234.42	\$1.12	\$0.93	\$577,488.05
26	944	2943	10	2009 Q2	ADVATE 401	3,392,028.00	463	\$3,986,332.51	\$3,864,660.22	\$71,672.29	\$1.14	\$0.93	\$110,074.18
27	944	2943	10	2009 Q3	ADVATE 801	4,976,011.00	329	\$6,037,631.51	\$5,818,062.70	\$219,568.81	\$1.17	\$0.93	\$1,374,016.50
28	944	2943	10	2009 Q4	ADVATE 801	5,593,085.99	392	\$6,951,427.46	\$6,575,595.77	\$375,831.69	\$1.18	\$0.93	\$964,139.42
29	944	2943	10	2009 Q1	ADVATE 801	3,789,447.00	278	\$4,849,246.39	\$4,493,905.13	\$355,344.26	\$1.15	\$0.93	\$394,016.50
30	944	2943	10	2009 Q2	ADVATE 801	4,461,275.84	278	\$5,154,907.91	\$4,948,232.11	\$206,675.80	\$1.15	\$0.93	\$1,002,791.78
31	944	2943	10	2009 Q3	ADVATE 1.2	3,978,478.00	227	\$4,811,856.80	\$4,548,232.11	\$263,624.69	\$1.11	\$0.93	\$396,057.57
32	944	2944	10	2009 Q4	ADVATE 1.2	6,139,151.60	226	\$7,261,856.80	\$6,924,556.34	\$337,300.46	\$1.16	\$0.93	\$1,019,550.53
33	944	2944	10	2009 Q1	ADVATE 1.2	5,093,346.00	284	\$6,631,902.54	\$6,142,966.39	\$488,936.15	\$1.12	\$0.93	\$940,613.82
34	944	2944	10	2009 Q2	ADVATE 1.2	5,593,346.00	284	\$6,631,902.54	\$6,142,966.39	\$488,936.15	\$1.12	\$0.93	\$940,613.82
35	944	2944	10	2009 Q3	ADVATE 1.8	9,250,878.23	318	\$10,926,184.59	\$10,405,099.85	\$521,084.74	\$1.06	\$0.93	\$1,001,068.90
36	944	2945	10	2009 Q4	ADVATE 1.8	12,240,037.00	411	\$13,830,712.74	\$12,795,292.51	\$1,034,420.23	\$1.05	\$0.93	\$1,019,550.53
37	944	2945	10	2009 Q1	ADVATE 1.8	7,940,482.00	310	\$9,812,005.51	\$8,425,714.62	\$1,386,290.89	\$1.09	\$0.93	\$1,019,550.53
38	944	2945	10	2009 Q2	ADVATE 1.8	9,575,635.00	306	\$10,946,057.24	\$9,476,623.66	\$1,469,433.58	\$1.09	\$0.93	\$1,019,550.53
39	944	2946	10	2009 Q3	ADVATE 2.4	11,725,280.00	309	\$13,460,172.36	\$12,764,830.87	\$695,341.49	\$1.12	\$0.93	\$1,019,550.53
40	944	2946	10	2009 Q4	ADVATE 2.4	14,308,934.00	388	\$17,135,674.79	\$16,026,920.64	\$1,108,754.15	\$1.12	\$0.93	\$1,019,550.53
41	944	2946	10	2009 Q1	ADVATE 2.4	12,021,529.00	361	\$14,565,353.85	\$13,628,020.46	\$937,333.39	\$1.13	\$0.93	\$1,019,550.53
42	944	2946	10	2009 Q2	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
43	944	2946	10	2009 Q3	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
44	944	2946	10	2009 Q4	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
45	944	2946	10	2009 Q1	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
46	944	2946	10	2009 Q2	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
47	944	2946	10	2009 Q3	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
48	944	2946	10	2009 Q4	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
49	944	2946	10	2009 Q1	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
50	944	2946	10	2009 Q2	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53
51	944	2946	10	2009 Q3	ADVATE 2.4	14,425,550.62	395	\$17,368,323.55	\$16,128,979.43	\$1,238,344.12	\$1.12	\$0.93	\$1,019,550.53

Less: Reimbursements in Excess of PAC to
Settling States Hawaii and Illinois:TOTAL AMOUNT MEDICAID REIMBURSED IN
EXCESS OF PAC FOR 2009:

\$401,003.25

\$28,755,721.57

2008 (Q1-Q4)

A	B	C	D	E	F	G	H	I	J	K	L	M	N
STATE CODE	LABEL CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED	MEDICAID AMOUNT REIMBURSED	NON-MEDICAID AMOUNT REIMBURSED	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1	944	2940	1	2008 Q1	ADVATE 250	243,146.00	56	\$303,880.22	\$303,880.22	\$0.00	\$1.25	\$0.92	\$80,185.90
2	944	2940	1	2008 Q2	ADVATE 250	154,011.00	32	\$211,232.49	\$193,263.58	\$17,968.91	\$1.25	\$0.92	\$51,573.46
3	944	2940	1	2008 Q3	ADVATE 250	48,521.00	13	\$68,338.81	\$68,338.81	\$0.00	\$1.41	\$0.92	\$23,689.48
4	944	2940	1	2008 Q4	ADVATE 250	21,918.00	6	\$25,040.33	\$25,040.33	\$0.00	\$1.14	\$0.92	\$4,875.77
5	944	2940	2	2008 Q1	ADVATE 500	298,973.00	48	\$370,949.38	\$369,730.48	\$1,218.90	\$1.24	\$0.92	\$94,767.32
6	944	2940	2	2008 Q2	ADVATE 500	161,027.00	19	\$194,659.04	\$189,708.24	\$5,150.80	\$1.18	\$0.92	\$41,563.40
7	944	2940	2	2008 Q3	ADVATE 500	89,859.00	14	\$118,947.90	\$118,947.90	\$0.00	\$1.32	\$0.92	\$36,277.62
8	944	2940	2	2008 Q4	ADVATE 500	137,378.00	11	\$115,912.52	\$115,912.52	\$0.00	\$1.36	\$0.92	\$37,449.40
9	944	2940	3	2008 Q1	ADVATE 1,0	605,971.00	10	\$721,368.80	\$1,271,368.80	\$18.00	\$0.93	\$0.92	\$27,742.30
10	944	2940	3	2008 Q2	ADVATE 1,0	208,976.00	38	\$242,499.48	\$529,751.02	\$6,915.00	\$0.87	\$0.92	\$87,566.96
11	944	2940	3	2008 Q3	ADVATE 1,0	42,004.00	12	\$143,757.81	\$279,824.88	\$33,280.80	\$1.34	\$0.92	\$11,833.33
12	944	2940	3	2008 Q4	ADVATE 1,0	606,299.00	12	\$725,830.98	\$50,477.01	\$224.00	\$1.20	\$0.92	\$167,811.90
13	944	2940	4	2008 Q1	ADVATE 1,5	250,174.00	24	\$284,222.36	\$725,606.98	\$11,125.37	\$1.09	\$0.92	\$42,936.91
14	944	2940	4	2008 Q2	ADVATE 1,5	131,171.00	5	\$178,468.57	\$166,628.53	\$11,841.04	\$1.27	\$0.92	\$45,951.21
15	944	2940	4	2008 Q3	ADVATE 1,5	143,601.00	9	\$203,894.90	\$40,778.98	\$163,115.92	\$0.28	\$0.92	\$91,333.94
16	944	2940	4	2008 Q4	ADVATE 1,5	46,247.00	2	\$44,932.98	\$21,532.98	\$23,400.00	\$0.47	\$0.92	\$21,014.26
17	944	2940	10	2008 Q1	ADVATE 1,8	15,840.00	5	\$3,405.77	\$33,631.65	\$11,863.08	\$0.84	\$0.92	\$3,422.27
18	944	2940	10	2008 Q2	ADVATE 1,8	15,840.00	1	\$17,040.84	\$3,405.77	\$13,635.07	\$0.22	\$0.92	\$11,167.03
19	944	2940	10	2008 Q3	ADVATE 1,8	863,233.00	1	\$19,225.00	\$3,405.77	\$15,819.23	\$1.25	\$0.92	\$5,072.40
20	944	2940	10	2008 Q4	ADVATE 1,8	843,895.00	237	\$1,043,431.65	\$1,009,655.58	\$33,776.07	\$1.17	\$0.92	\$215,461.22
21	944	2941	10	2008 Q1	ADVATE 200	1,232,899.00	231	\$1,046,598.44	\$1,035,723.34	\$10,875.10	\$1.23	\$0.92	\$259,827.54
22	944	2941	10	2008 Q2	ADVATE 200	1,167,817.00	303	\$1,471,352.49	\$1,420,231.78	\$51,120.71	\$1.15	\$0.92	\$285,964.70
23	944	2941	10	2008 Q3	ADVATE 200	1,173,218.00	286	\$1,375,364.81	\$1,301,305.96	\$74,058.85	\$1.11	\$0.92	\$227,096.32
24	944	2942	10	2008 Q4	ADVATE 401	2,549,956.00	283	\$2,011,816.36	\$2,007,488.16	\$4,330.20	\$1.13	\$0.92	\$376,127.60
25	944	2942	10	2008 Q1	ADVATE 401	3,015,138.00	389	\$3,090,997.78	\$3,084,484.70	\$6,513.08	\$1.21	\$0.92	\$738,525.18
26	944	2942	10	2008 Q2	ADVATE 401	3,168,608.00	422	\$3,601,428.07	\$3,601,428.07	\$0.00	\$1.19	\$0.92	\$827,501.11
27	944	2942	10	2008 Q3	ADVATE 401	3,795,395.00	445	\$4,696,724.61	\$3,663,960.11	\$1,155,903.21	\$1.16	\$0.92	\$747,938.37
28	944	2943	10	2008 Q4	ADVATE 801	4,592,871.00	445	\$5,672,815.08	\$4,657,357.64	\$999,956.33	\$1.24	\$0.92	\$1,182,282.52
29	944	2943	10	2008 Q1	ADVATE 801	4,592,871.00	337	\$5,672,815.08	\$5,313,216.75	\$359,996.33	\$1.12	\$0.92	\$958,241.43
30	944	2943	10	2008 Q2	ADVATE 801	4,592,871.00	337	\$5,672,815.08	\$5,161,590.16	\$511,224.92	\$1.13	\$0.92	\$966,748.70
31	944	2943	10	2008 Q3	ADVATE 801	4,592,871.00	337	\$5,672,815.08	\$5,161,590.16	\$511,224.92	\$1.13	\$0.92	\$966,748.70
32	944	2943	10	2008 Q4	ADVATE 801	4,592,871.00	337	\$5,672,815.08	\$5,161,590.16	\$511,224.92	\$1.13	\$0.92	\$966,748.70
33	944	2943	10	2008 Q1	ADVATE 1,2	5,025,704.00	193	\$4,719,890.95	\$4,719,890.95	\$0.00	\$1.19	\$0.92	\$1,063,805.58
34	944	2944	10	2008 Q2	ADVATE 1,2	5,025,704.00	240	\$5,938,150.51	\$4,719,890.95	\$1,218,259.56	\$1.12	\$0.92	\$1,063,805.58
35	944	2944	10	2008 Q3	ADVATE 1,2	5,025,704.00	240	\$5,938,150.51	\$4,719,890.95	\$1,218,259.56	\$1.12	\$0.92	\$1,063,805.58
36	944	2944	10	2008 Q4	ADVATE 1,2	5,025,704.00	240	\$5,938,150.51	\$4,719,890.95	\$1,218,259.56	\$1.12	\$0.92	\$1,063,805.58
37	944	2944	10	2008 Q1	ADVATE 1,8	4,254,031.00	312	\$7,253,961.72	\$5,038,174.32	\$2,215,787.40	\$1.17	\$0.92	\$1,649,815.56
38	944	2945	10	2008 Q2	ADVATE 1,8	4,254,031.00	228	\$5,038,174.32	\$4,756,673.85	\$281,500.48	\$1.06	\$0.92	\$1,297,955.93
39	944	2945	10	2008 Q3	ADVATE 1,8	4,254,031.00	231	\$7,961,306.08	\$7,696,424.02	\$264,882.06	\$1.07	\$0.92	\$1,297,955.93
40	944	2945	10	2008 Q4	ADVATE 1,8	4,254,031.00	231	\$7,961,306.08	\$7,696,424.02	\$264,882.06	\$1.07	\$0.92	\$1,297,955.93
41	944	2945	10	2008 Q1	ADVATE 1,8	9,507,401.00	358	\$10,111,584.00	\$10,111,584.00	\$0.00	\$1.08	\$0.92	\$1,632,878.94
42	944	2946	10	2008 Q2	ADVATE 2,4	6,133,889.00	143	\$11,864,850.37	\$10,935,536.22	\$929,314.15	\$1.13	\$0.92	\$1,263,835.07
43	944	2946	10	2008 Q3	ADVATE 2,4	7,971,281.00	181	\$9,255,788.88	\$6,927,012.95	\$2,328,775.93	\$1.10	\$0.92	\$1,418,125.94
44	944	2946	10	2008 Q4	ADVATE 2,4	10,774,255.75	281	\$12,641,239.43	\$11,966,351.05	\$674,888.38	\$1.11	\$0.92	\$2,054,035.75
45	944	2946	10	2008 Q1	ADVATE 2,4	11,347,133.02	284	\$12,332,654.42	\$12,332,654.42	\$0.00	\$1.09	\$0.92	\$1,853,883.67
46													\$25,812,270.80
47													\$6,213,793.99
48													\$6,213,793.99
49													\$6,213,793.99
50													\$6,213,793.99
51													\$6,213,793.99
52													\$6,213,793.99
53													\$6,213,793.99
54													\$6,213,793.99

Less: Reimbursements in Excess of PAC to
Settling States California, Hawaii, Illinois, and
Nevada:

TOTAL AMOUNT MEDICAID REIMBURSED IN
EXCESS OF PAC FOR 2008:

\$19,598,476.81

2007 (Q1-Q4)

	A	B	C	D	E	F	G	H	I	L	M	N
	STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED*	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1		944	2940	1	2007 Q1	ADVATE 250	946,659.00	186	\$1,177,038.28	\$1.24	\$0.94	\$287,178.82
2		944	2940	1	2007 Q2	ADVATE 250	687,889.00	150	\$828,702.28	\$1.20	\$0.94	\$182,086.62
3		944	2940	1	2007 Q3	ADVATE 250	682,585.00	105	\$812,380.46	\$1.23	\$0.94	\$189,550.56
4		944	2940	1	2007 Q4	ADVATE 250	280,599.00	86	\$333,036.03	\$1.19	\$0.94	\$69,310.57
5		944	2940	2	2007 Q1	ADVATE 500	2,319,437.00	321	\$2,608,837.87	\$1.12	\$0.94	\$428,567.09
6		944	2940	2	2007 Q2	ADVATE 500	1,613,342.00	237	\$1,880,576.31	\$1.17	\$0.94	\$364,034.83
7		944	2940	2	2007 Q3	ADVATE 500	746,370.00	122	\$780,669.02	\$1.05	\$0.94	\$79,081.22
8		944	2940	2	2007 Q4	ADVATE 500	505,991.00	84	\$602,174.13	\$1.19	\$0.94	\$126,542.59
9		944	2940	3	2007 Q1	ADVATE 1.0	5,772,517.00	323	\$6,086,215.91	\$1.05	\$0.94	\$660,049.93
10		944	2940	3	2007 Q2	ADVATE 1.0	3,068,538.00	232	\$3,445,704.98	\$1.12	\$0.94	\$561,279.26
11		944	2940	3	2007 Q3	ADVATE 1.0	2,688,453.00	168	\$3,070,044.64	\$1.14	\$0.94	\$542,888.62
12		944	2940	3	2007 Q4	ADVATE 1.0	1,906,925.00	136	\$2,089,760.14	\$1.10	\$0.94	\$297,250.64
13		944	2940	4	2007 Q1	ADVATE 1.5	5,862,992.00	249	\$6,904,151.16	\$1.17	\$0.94	\$1,364,738.68
14		944	2940	4	2007 Q2	ADVATE 1.5	4,233,738.00	157	\$4,581,415.19	\$1.08	\$0.94	\$601,701.47
15		944	2940	4	2007 Q3	ADVATE 1.5	2,122,769.00	70	\$2,169,375.64	\$1.02	\$0.94	\$173,972.78
16		944	2940	4	2007 Q4	ADVATE 1.5	1,243,969.00	44	\$1,461,692.43	\$1.18	\$0.94	\$292,361.57
17		944	2940	10	2007 Q1	ADVATE 1.8	5,494,289.00	158	\$6,607,391.54	\$1.20	\$0.94	\$1,442,759.88
18		944	2940	10	2007 Q2	ADVATE 1.8	2,329,994.00	77	\$2,599,887.06	\$1.12	\$0.94	\$409,692.70
19		944	2940	10	2007 Q3	ADVATE 1.8	1,779,783.00	48	\$2,182,299.61	\$1.23	\$0.94	\$509,303.59
20		944	2940	10	2007 Q4	ADVATE 1.8	651,692.00	20	\$704,302.00	\$1.08	\$0.94	\$91,711.52
21		944	2941	10	2007 Q1	ADVATE 200	175,586.00	17	\$201,590.53	\$1.15	\$0.94	\$36,539.69
22		944	2941	10	2007 Q2	ADVATE 200	678,565.00	146	\$816,397.19	\$1.20	\$0.94	\$178,546.09
23		944	2941	10	2007 Q3	ADVATE 200	868,244.00	244	\$1,062,413.88	\$1.22	\$0.94	\$246,264.52
24		944	2941	10	2007 Q4	ADVATE 200	787,285.00	216	\$934,373.18	\$1.19	\$0.94	\$194,325.28
25		944	2942	10	2007 Q1	ADVATE M	108,360.00	14	\$144,897.77	\$1.34	\$0.94	\$43,039.37
26		944	2942	10	2007 Q2	ADVATE 401	773,655.00	132	\$948,254.90	\$1.23	\$0.94	\$221,019.20
27		944	2942	10	2007 Q3	ADVATE 401	1,366,832.00	224	\$1,648,587.77	\$1.21	\$0.94	\$363,765.69
28		944	2942	10	2007 Q4	ADVATE 401	1,520,546.00	222	\$1,797,984.10	\$1.18	\$0.94	\$368,680.86
29		944	2943	10	2007 Q1	ADVATE H	156,555.00	9	\$262,043.79	\$1.67	\$0.94	\$114,882.09
30		944	2943	10	2007 Q2	ADVATE 801	1,605,994.00	116	\$1,934,106.58	\$1.20	\$0.94	\$424,472.22
31		944	2943	10	2007 Q3	ADVATE 801	3,751,663.00	264	\$4,421,957.22	\$1.18	\$0.94	\$895,394.00
32		944	2943	10	2007 Q4	ADVATE 801	4,066,213.80	288	\$4,947,319.62	\$1.22	\$0.94	\$1,125,078.65
33		944	2944	10	2007 Q1	ADVATE SH	145,500.00	7	\$180,478.10	\$1.24	\$0.94	\$43,708.10
34		944	2944	10	2007 Q2	ADVATE 1.2	3,103,959.00	135	\$3,686,527.08	\$1.19	\$0.94	\$770,805.62
35		944	2944	10	2007 Q3	ADVATE 1.2	5,498,315.20	231	\$6,387,248.04	\$1.16	\$0.94	\$1,218,831.75
36		944	2944	10	2007 Q4	ADVATE 1.2	4,606,067.03	196	\$5,460,813.78	\$1.19	\$0.94	\$1,131,110.78
37		944	2945	10	2007 Q1	ADVATE 1.8	1,123,840.00	27	\$1,288,696.02	\$1.15	\$0.94	\$232,286.42
38		944	2945	10	2007 Q2	ADVATE 1.8	5,421,210.00	142	\$6,549,833.32	\$1.21	\$0.94	\$1,453,895.92
39		944	2945	10	2007 Q3	ADVATE 1.8	6,486,305.00	180	\$7,732,611.73	\$1.20	\$0.94	\$1,663,685.03
40		944	2945	10	2007 Q4	ADVATE 1.8	6,274,958.00	201	\$7,254,500.34	\$1.16	\$0.94	\$1,356,039.82
41		944	2946	10	2007 Q1	ADVATE 2.4	372,627.00	11	\$497,251.26	\$1.33	\$0.94	\$146,981.88
42		944	2946	10	2007 Q2	ADVATE 2.4	4,159,109.00	96	\$4,914,161.62	\$1.18	\$0.94	\$1,004,599.16
43		944	2946	10	2007 Q3	ADVATE 2.4						
44		944	2946	10	2007 Q4	ADVATE 2.4						
45												\$21,908,025.28
46												
47												
48												\$4,146,189.71
49												
50												
51												
52												
53												
54												
55												
56												
57												
58												
59												
60												
61												

Less: Reimbursements in Excess of PAC to Settling States California, Hawaii, Illinois, and Nevada:

TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC FOR 2007:

\$17,761,835.57

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

Less: Reimbursements in Excess of PAC to
Settling States California, Hawaii, Illinois, and
Nevada.

TOTAL AMOUNT MEDICAID REIMBURSED IN
EXCESS OF PAC FOR 2007:

\$17,761,835.57

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

2006 (Q1-Q4)

	A	B	C	D	E	F	G	H	I	L	M	N
	STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1	US	944	2940	1	2006 Q1	ADVATE 250	439,068.00	129	\$567,792.74	\$1.29	\$0.93	\$159,440.90
2	US	944	2940	1	2006 Q2	ADVATE 250	880,030.00	175	\$1,139,633.97	\$1.29	\$0.93	\$321,206.07
3	US	944	2940	1	2006 Q3	ADVATE 250	937,676.00	182	\$1,203,237.27	\$1.28	\$0.93	\$331,198.99
4	US	944	2940	1	2006 Q4	ADVATE 250	1,073,134.00	215	\$1,352,662.96	\$1.26	\$0.93	\$354,648.33
5	US	944	2940	2	2006 Q1	ADVATE 500	1,962,771.00	269	\$2,548,810.67	\$1.30	\$0.93	\$723,433.64
6	US	944	2940	2	2006 Q2	ADVATE 500	2,493,513.00	282	\$2,557,540.94	\$1.03	\$0.93	\$238,573.85
7	US	944	2940	2	2006 Q3	ADVATE 500	2,774,855.00	300,309	\$3,853,836.55	\$1.39	\$0.93	\$1,273,221.40
8	US	944	2940	2	2006 Q4	ADVATE 500	2,698,461.00	362	\$3,692,484.41	\$1.37	\$0.93	\$1,182,915.68
9	US	944	2940	3	2006 Q1	ADVATE 100	7,768,838.00	512	\$9,498,378.66	\$1.22	\$0.93	\$2,254,759.32
10	US	944	2940	3	2006 Q2	ADVATE 100	9,635,171.00	565	\$11,682,907.36	\$1.21	\$0.93	\$2,722,198.33
11	US	944	2940	3	2006 Q3	ADVATE 100	8,697,731.00	690,537	\$11,139,030.42	\$1.28	\$0.93	\$3,050,140.58
12	US	944	2940	3	2006 Q4	ADVATE 100	6,794,524.00	427	\$7,932,514.77	\$1.17	\$0.93	\$1,613,607.45
13	US	944	2940	4	2006 Q1	ADVATE 150	4,907,511.00	169	\$6,555,868.73	\$1.34	\$0.93	\$1,991,883.50
14	US	944	2940	4	2006 Q2	ADVATE 150	5,827,371.80	212	\$7,239,265.44	\$1.24	\$0.93	\$1,819,809.67
15	US	944	2940	4	2006 Q3	ADVATE 150	5,870,111.00	260,210	\$7,166,678.36	\$1.22	\$0.93	\$1,707,475.13
16	US	944	2940	4	2006 Q4	ADVATE 150	6,519,655.00	276	\$7,999,683.65	\$1.23	\$0.93	\$1,936,404.50
17	US	944	2940	10	2006 Q1	ADVATE 1.8	510,260.00	14	\$701,931.02	\$1.38	\$0.93	\$227,389.22
18	US	944	2940	10	2006 Q2	ADVATE 1.8	2,215,670.00	640,057	\$2,949,086.03	\$1.33	\$0.93	\$888,512.93
19	US	944	2940	10	2006 Q3	ADVATE 180	5,247,306.00	158	\$6,433,843.88	\$1.23	\$0.93	\$1,553,849.30
20	US	944	2940	10	2006 Q4	ADVATE 200						
21												\$24,350,688.40
22												
23												
24												
25												
26												
27												
28												
29												
30												
31												
32												
33												
34												
35												
36												
37												
38												
39												
40												
41												
42												
43												

Less: Reimbursements in Excess of PAC to
Settling States California, Hawaii, Illinois,
Nevada and Texas.

**TOTAL AMOUNT MEDICAID REIMBURSED
IN EXCESS OF PAC FOR 2006:**

\$19,746,719.87

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

2005 (Q1-Q4)

	A	B	C	D	E	F	G	H	I	L	M	N
	STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1	US	944	2940	1	2005 Q1	ADVATE 250	416,005.00	100	\$531,328.95	\$1.28	\$0.90	\$156,924.45
2	US	944	2940	1	2005 Q2	ADVATE 250	511,926.00	129	\$613,294.23	\$1.20	\$0.90	\$152,560.33
3	US	944	2940	1	2005 Q3	ADVATE 250	739,404.00	164	\$911,248.47	\$1.23	\$0.90	\$245,784.87
4	US	944	2940	1	2005 Q4	ADVATE 250	947,550.00	165	\$1,151,071.55	\$1.21	\$0.90	\$298,276.55
5	US	944	2940	2	2005 Q1	ADVATE 500	1,092,703.00	144	\$1,298,919.53	\$1.19	\$0.90	\$315,486.83
6	US	944	2940	2	2005 Q2	ADVATE 500	1,340,394.00	215	\$1,840,153.91	\$1.37	\$0.90	\$633,799.31
7	US	944	2940	2	2005 Q3	ADVATE 500	1,440,079.00	243	\$2,084,042.18	\$1.45	\$0.90	\$787,971.08
8	US	944	2940	2	2005 Q4	ADVATE 500	1,680,970.00	240	\$2,426,791.55	\$1.44	\$0.90	\$913,918.55
9	US	944	2940	3	2005 Q1	ADVATE 100	5,307,170.00	318	\$6,650,572.19	\$1.25	\$0.90	\$1,874,119.19
10	US	944	2940	3	2005 Q2	ADVATE 100	6,124,058.00	399	\$7,565,787.31	\$1.24	\$0.90	\$2,054,135.11
11	US	944	2940	3	2005 Q3	ADVATE 100	8,200,007.00	522	\$9,785,391.58	\$1.19	\$0.90	\$2,405,385.28
12	US	944	2940	3	2005 Q4	ADVATE 100	7,818,969.00	489	\$9,285,104.39	\$1.19	\$0.90	\$2,248,032.29
13	US	944	2940	4	2005 Q1	ADVATE 150	3,774,201.00	162	\$4,465,298.98	\$1.18	\$0.90	\$1,068,518.08
14	US	944	2940	4	2005 Q2	ADVATE 150	4,097,831.00	160	\$5,052,180.80	\$1.23	\$0.90	\$1,364,132.90
15	US	944	2940	4	2005 Q3	ADVATE 150	4,953,597.00	193	\$5,978,496.19	\$1.21	\$0.90	\$1,520,258.89
16	US	944	2940	4	2005 Q4	ADVATE 150	5,245,504.00	198	\$6,392,916.47	\$1.22	\$0.90	\$1,671,962.87
17	US	944	2940	4								
18												
19												
20												
21												
22												
23												
24												
25												
26												
27												
28												
29												
30												
31												
32												
33												
34												
35												
36												
37												
Less: Reimbursements in Excess of PAC to Settling States California, Hawaii, Illinois, Nevada and Texas:												
TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC FOR 2005:												
\$13,861,813.01												

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

2004 (Q1-Q4)

A	B	C	D	E	F	G	H	I	J	K	L	M	N
STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC		
1	US	944	2940	1	2004 Q1 ADVATE 250	369,011.00	50	\$504,802.26	\$1.37	\$0.94	\$157,931.92		
2	US	944	2940	1	2004 Q2 ADVATE 250	578,289.00	64	\$776,192.79	\$1.34	\$0.94	\$232,601.13		
3	US	944	2940	1	2004 Q3 ADVATE 250	531,278.00	88	\$553,487.00	\$1.04	\$0.94	\$54,085.68		
4	US	944	2940	1	2004 Q4 ADVATE 250	421,519.00	93	\$537,502.74	\$1.28	\$0.94	\$141,274.88		
5	US	944	2940	2	2004 Q1 ADVATE 500	339,608.00	56	\$496,834.60	\$1.46	\$0.94	\$177,603.08		
6	US	944	2940	2	2004 Q2 ADVATE 500	572,410.00	90	\$814,620.30	\$1.42	\$0.94	\$276,554.90		
7	US	944	2940	2	2004 Q3 ADVATE 500	979,833.00	146	\$1,351,910.23	\$1.38	\$0.94	\$430,867.21		
8	US	944	2940	2	2004 Q4 ADVATE 500	1,273,448.00	160	\$1,742,236.39	\$1.37	\$0.94	\$545,195.27		
9	US	944	2940	3	2004 Q1 ADVATE 100	1,785,335.00	145	\$2,567,433.02	\$1.44	\$0.94	\$889,218.12		
10	US	944	2940	3	2004 Q2 ADVATE 100	3,357,195.00	225	\$4,851,097.30	\$1.44	\$0.94	\$1,695,334.00		
11	US	944	2940	3	2004 Q3 ADVATE 100	4,376,715.04	267	\$5,979,887.53	\$1.37	\$0.94	\$1,865,775.39		
12	US	944	2940	3	2004 Q4 ADVATE 100	4,990,051.00	330	\$6,500,003.53	\$1.30	\$0.94	\$1,809,355.59		
13	US	944	2940	4	2004 Q1 ADVATE 150	2,151,813.00	119	\$3,120,759.70	\$1.45	\$0.94	\$1,098,055.48		
14	US	944	2940	4	2004 Q2 ADVATE 150	2,716,232.00	146	\$3,599,362.15	\$1.33	\$0.94	\$1,046,104.07		
15	US	944	2940	4	2004 Q3 ADVATE 150	2,661,368.00	97	\$3,488,458.59	\$1.31	\$0.94	\$986,772.67		
16	US	944	2940	4	2004 Q4 ADVATE 150	2,292,257.00	98	\$2,869,032.28	\$1.25	\$0.94	\$714,310.70		
17	US	944	2940										
18													
19													
20													
21													
22													
23													
24													
25													
26													
27													
28													
29													
30													
31													
32													
33													
34													
35													
36													
37													

Less: Reimbursements in Excess of PAC to Settling States of California, Hawaii, Illinois, Nevada and Texas:

\$2,171,181.87

TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC FOR 2004:

\$9,949,858.22

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

Less: Reimbursements in Excess of PAC to Settling States of California, Hawaii, Illinois, Nevada and Texas:

TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC FOR 2004:

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

\$2,171,181.87

\$9,949,858.22

\$12,121,040.09

2003 (Q3-Q4)

	A	B	C	D	E	F	G	H	I	L	M	N
	STATE CODE	LABELER CODE	PRODUCT CODE	PACKAGE SIZE	PERIOD COVERED (BY QUARTER)	PRODUCT FDA LIST NAME	UNITS REIMBURSED	NO. OF PRESCRIPTIONS	TOTAL AMOUNT REIMBURSED*	REIMBURSEMENT/UNIT ("RPI")	PHARMACY ACQUISITION COST ("PAC")	AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC
1	US	944	2940	1	2003 Q3	ADVATE ANT	2,436.00	1	\$4,034.38	\$1.66	\$1.05	\$1,476.58
2	US	944	2940	1	2003 Q4	ADVATE 250	337,825.00	45	\$491,211.85	\$1.45	\$1.05	\$136,495.60
3	US	944	2940	2	2003 Q3	ADVATE 500	11,840.00	2	\$16,748.66	\$1.41	\$1.05	\$4,316.66
4	US	944	2940	2	2003 Q4	ADVATE 500	191,360.00	30	\$277,638.11	\$1.45	\$1.05	\$76,710.11
5	US	944	2940	3	2003 Q3	ADVATE ANT	27,612.00	5	\$38,735.84	\$1.40	\$1.05	\$9,743.24
6	US	944	2940	3	2003 Q4	ADVATE 100	1,352,364.00	151	\$1,913,343.52	\$1.41	\$1.05	\$493,361.32
7	US	944	2940	4	2003 Q3	ADVATE 150	58,979.00	13	\$97,350.08	\$1.65	\$1.05	\$35,422.13
8	US	944	2940	4	2003 Q4	ADVATE 150	1,475,028.00	121	\$2,196,521.79	\$1.49	\$1.05	\$647,742.39
9	US	944	2940									
10												
11												
12												
13												
14												
15												
16												
17												
18												
19												
20												
21												
22												
23												
24												
25												
26												
27												
28												
29												
30												

Less: Reimbursements in Excess of PAC to Settling States California, Hawaii, Illinois, Nevada and Texas:

\$1,405,268.03

\$318,402.26

TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS OF PAC FOR 2003:

\$1,086,865.77

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

Less: Reimbursements in Excess of PAC to Settling
States California, Hawaii, Illinois, Nevada and Texas:

TOTAL AMOUNT MEDICAID REIMBURSED IN EXCESS
OF PAC FOR 2003:

\$1,405,268.03

\$318,402.26

\$1,086,865.77

* Beginning in Q4 2007, the reporting requirements were changed so that reimbursement amounts were reflected in two categories: "Medicaid Amount Reimbursed" and "Non-Medicaid Amount Reimbursed." Prior to Q4 2007, splitting the data into two categories was not required and was, therefore, reported inconsistently. Thus, "Total Amount Reimbursed" was used for years 2003 - 2007 to determine reimbursement per unit ("RPI").

Exhibit 2



(1)

[Return to previous page](#)

[Home \(1\)](#) > [Medicaid \(/Medicaid-CHIP-Program-Information/Medicaid-and-CHIP-Program-Information.html\)](#) > [By Topic \(/Medicaid-CHIP-Program-Information/By-Topics/By-Topic.html\)](#) > [Benefits \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Medicaid-Benefits.html\)](#) > Prescription Drugs

Medicaid Drug Rebate Program Data

Product Data for Drugs in the Medicaid Drug Rebate Program

The [rebate drug product data file \[ZIP\] \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/DrugProductDataFile2Q2012.zip\)](#) contains the active drugs that have been reported by participating drug manufacturers as of the most recent rebate reporting period under the Medicaid Drug Rebate Program. All drugs are identified by National Drug Code (NDC), unit type, units per package size, product name, Food and Drug Administration (FDA) approval date, the date the drug entered the market, plus indicators to show whether the drug is an innovator or non-innovator drug; whether it is available by prescription or over-the-counter (OTC); the FDA therapeutic equivalency code; and the Drug Efficacy Study Implementation (DESI) rating and termination date, if applicable. (Note: Only active drugs and drugs with a termination date on or after the last processed quarter are included in the file). For your convenience, we are also providing you the [record specification and definitions for the drug product data file \[PDF\] \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/RecordSpecificationandDefinitions.pdf\)](#).

Quarterly Average Manufacturer Price (AMP) Data for Drugs in the Medicaid Drug Rebate Program: Reported or Not Reported

In accordance with the terms of the National Drug Rebate Agreement and section 1927(b)(3)(A) of the Social Security Act (the Act), drug manufacturers participating in the Medicaid Drug Rebate Program are required to report AMP information to the Centers for Medicare & Medicaid Services (CMS) each quarter. A quarterly AMP must be reported for each active drug that the manufacturer has reported for inclusion in the Medicaid Drug Rebate Program. Failure to submit the required AMP data may result in penalties, such as the drug manufacturer's termination from the rebate program or the issuance of civil monetary penalties by the Office of the Inspector General.

In an effort to improve the timeliness of the data CMS receives from drug manufacturers each quarter, CMS is posting the [quarterly AMP reported or not reported file \[ZIP\] \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/Reportingof2Q2012AMPData.zip\)](#). This file contains the active drugs that have been submitted as of the most recent reporting period under the Medicaid Drug Rebate Program, along with an indication of whether or not the required AMP was reported for each drug. All drugs are identified in the file by the 11-digit National Drug Code (NDC), product name, labeler name, and reported (R) or not reported (NR). Please note that, due to confidentiality provisions found in section 1927(b)(3)(D) of the Act, this file does not contain actual AMP values; rather, it simply notes whether or not CMS received an AMP for each drug included in the file. Further, the file only reflects AMP data that was received at the time that Medicaid drug rebates were calculated for the most recent reporting period. Finally, the only terminated drugs included in this file are those that are being terminated within the quarter represented in the file, or those with a termination date in the future.

State Utilization Data

Drug utilization for States are available for covered outpatient drugs paid for by State Medicaid agencies since the start of the Medicaid Drug Rebate Program. To download these data, please use the [State drug utilization data specifications \[PDF\] \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/StateUtilizationDataSpecifications.pdf\)](#).

Prescription Drug Content

- [Covered Outpatient Drugs Policy \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Covered-Outpatient-Drugs-Policy.html\)](#)
- [Drug Utilization Review \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Drug-Utilization-Review.html\)](#)
- [Federal Upper Limits \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Federal-Upper-Limits.html\)](#)
- [Medicaid Drug Rebate Program \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html\)](#)
- [Medicaid Drug Rebate Program Data \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program-Data.html\)](#)
- [Medicaid Drug Rebate Program Dispute Resolution \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program-Dispute-Resolution.html\)](#)
- [National Drug Rebate Agreement \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/National-Drug-Rebate-Agreement.html\)](#)

Please note that this format includes two new fields: Medicaid Amount Reimbursed and Non-Medicaid Amount Reimbursed. The sum of these two fields should generally equal the Total Amount Reimbursed on an NDC by NDC basis; however, these new fields were implemented beginning with the fourth quarter of 2007 and are optional for the states to report prior to that time. Therefore, for quarters earlier than fourth quarter 2007, there may be some large discrepancies between the Total Amount Reimbursed and the sum of the Medicaid Amount Reimbursed and the Non-Medicaid Amount Reimbursed because the Non-Medicaid Amount Reimbursed is often not present for those earlier quarters. Should you notice apparent discrepancies in an individual state's utilization data, your questions should be directed to that state's Technical Contact.

How often are the State Utilization Data and the National Summary Utilization Data [Dynamic List - ZIP] (<http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Programs-Data-and-Resources.html>) updated and posted to the website?

1st Quarter (plus 5 preceding years of data): August
 2nd Quarter (plus 5 preceding years of data): November
 3rd Quarter (plus 5 preceding years of data): February
 (<http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Programs-Data-and-Resources.html>)
 4th Quarter (plus 5 preceding years of data): May

State utilization data older than the current quarter plus five previous years of data are updated annually and posted to the website during the month of February. The national summary utilization data are aggregate data by NDC-11.

Last Update: August Cycle - 1st Quarter (plus 5 preceding years of data):

Questions about the Medicaid Drug Rebate Program's data? Email MDROperations@cms.hhs.gov (mailto:MDROperations@cms.hhs.gov?subject=MDROperations%20Question%20from%20Medicaid.gov).

- [Program Releases \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Program-Releases.html\)](#)
- [State Prescription Drug Resources \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/State-Prescription-Drug-Resources.html\)](#)
- [Survey of Retail Prices \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Survey-of-Retail-Prices.html\)](#)
- [Medicaid Drug Programs Data & Resources \(/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Programs-Data-and-Resources.html\)](#)

Exhibit 3

MEDICAID STATE DRUG UTILIZATION DATA
Web File Structure and Definitions
August 2009

Fields are delimitedated with a vertical bar/pipe ("|")

Field	Size	Remarks
State Code	2	State Abbreviation
Labeler Code	5	NDC #1
Product Code	4	NDC #2
Package Size	2	NDC #3
Period Covered	5	YYYYQ (Yr/Qtr)
Product FDA List Name	10	Product Name as appears on FDA listing form (1st 10 characters)
Units Reimbursed	15	9999999999.999
No. of Prescriptions	9	999999999
Total Amount Reimbursed	15	99999999999.99
Medicaid Amount Reimbursed	13	999999999.99
Non-Medicaid Amount Reimbursed	13	999999999.99

UTILIZATION FIELD DEFINITIONS

State Abbreviation: Two character post office abbreviation for State.

Labeler Code: First segment of National Drug Code (NDC1) that identifies the manufacturer, labeler, relabeler, packager, repackager or distributor of the drug.

Product Code: Second segment of National Drug Code (NDC2).

Package Size: Third segment of National Drug Code (NDC3).

Period Covered: Calendar year and quarter covered by data.
Valid values for Q:
1 = January 1 – March 31
2 = April 1 – June 30
3 = July 1 – September 30
4 = October 1 – December 31

Product FDA List Name: (Abbreviated) – First 10 characters of product name as approved by the FDA listing form.

Units Reimbursed: The total number of units (based on Unit Type) of the drug (11-digit NDC level) reimbursed by the state during the period covered. [Numeric 15 positions: 11 whole numbers, decimal (.), 3 decimals]

No. of Prescriptions: The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered. [Numeric 9 whole numbers]

Total Amount Reimbursed: The total amount reimbursed by both Medicaid and non-Medicaid entities to pharmacies for the (11-digit NDC) drug in the period covered (two below fields added together). This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees. [Numeric 15 positions: 12 whole numbers, decimal (.), 2 decimal places]

Medicaid Amount Reimbursed: The amount reimbursed (by the Medicaid Program ONLY) to pharmacies for the (11-digit NDC) drug in the period covered. [Numeric 13 positions: 10 whole numbers, decimal (.), 2 decimal places]

Non-Medicaid Amount Reimbursed:

The amount reimbursed (by non-Medicaid entities) to pharmacies for the (11-digit NDC) drug in the period covered. The Non-Medicaid Amount Reimbursed includes any reimbursement amount for which the state is not eligible for Federal Matching Funds. [Numeric 13 positions: 10 whole numbers, decimal (.), 2 decimal places]

Exhibit 4

XX	00944	2940	01	20091	ADVATE	ANT	00000000260.000	0000000001	000000000263.50	0000000263.50	0000000000.00
XX	00944	2940	01	20092	ADVATE	ANT	00000001016.000	0000000001	000000001124.35	0000001124.35	0000000000.00
XX	00944	2940	01	20093	ADVATE	250	000000007083.000	0000000003	000000008288.79	0000008288.79	0000000000.00
XX	00944	2940	01	20094	ADVATE	250	00000002009.000	0000000004	000000001661.34	0000001661.34	0000000000.00
XX	00944	2940	02	20091	ADVATE	500	000000014199.000	0000000003	000000001915.14	0000001915.14	0000000000.00
XX	00944	2940	02	20092	ADVATE	ANT	000000012342.000	0000000005	0000000047352.05	0000047352.05	0000000000.00
XX	00944	2940	02	20093	ADVATE	500	000000027248.000	0000000011	000000004622.76	0000044622.76	0000000000.00
XX	00944	2940	02	20094	ADVATE	500	000000020239.000	0000000008	0000000016915.75	0000016915.75	0000000000.00
XX	00944	2940	03	20091	ADVATE	1,0	000000077253.000	0000000008	0000000095529.08	0000056605.88	0000038923.20
XX	00944	2940	03	20092	ADVATE	1,0	000000162403.000	0000000024	0000000389055.05	0000175545.02	0000213510.03
XX	00944	2940	03	20093	ADVATE	1,0	000000062506.000	0000000019	000000178116.04	0000107059.48	0000071056.56
XX	00944	2940	03	20094	ADVATE	1,0	000000098148.000	0000000018	000000117384.49	0000114194.17	0000003190.32
XX	00944	2940	04	20091	ADVATE	ANT	000000057302.000	0000000004	000000162603.79	0000085172.83	0000077430.96
XX	00944	2940	04	20092	ADVATE	1,5	000000071973.000	0000000009	000000223106.88	0000187191.67	0000035915.21
XX	00944	2940	04	20093	ADVATE	1,5	000000060750.000	0000000007	000000057712.50	0000057712.50	0000000000.00
XX	00944	2940	04	20094	ADVATE	1,5	000000013345.000	0000000003	000000014921.44	0000014921.44	0000000000.00
XX	00944	2940	10	20091	ADVATE	ANT	000000026460.000	0000000001	0000000028573.80	0000005712.36	0000022861.44
XX	00944	2940	10	20092	ADVATE	ANT	000000022680.000	0000000001	000000024491.40	0000004895.88	0000019595.52
XX	00944	2941	10	20091	ADVATE	200	000000873898.000	0000000231	000001037607.96	00001026982.82	0000010625.14
XX	00944	2941	10	20092	ADVATE	200	000001126099.000	0000000329	000001289824.56	0001286109.06	0000003715.50
XX	00944	2941	10	20093	ADVATE	200	000000906514.000	0000000236	000001109344.29	0001086347.70	0000022996.59
XX	00944	2941	10	20094	ADVATE	200	00001056065.000	0000000288	000001249108.97	0001230679.44	0000018429.53
XX	00944	2942	10	20091	ADVATE	401	00003268823.000	0000000429	000003923121.91	0003882663.64	0000040458.27
XX	00944	2942	10	20092	ADVATE	401	00003604938.000	0000000510	000004204112.58	0004168443.22	0000035669.36
XX	00944	2942	10	20093	ADVATE	401	00002978993.000	0000000412	000003461185.96	0003347951.54	0000113234.42
XX	00944	2942	10	20094	ADVATE	401	00003392028.000	0000000453	000003936332.51	0003864660.22	0000071672.29
XX	00944	2943	10	20091	ADVATE	801	00004976011.000	0000000329	000006037631.51	0005818062.70	0000219568.81
XX	00944	2943	10	20092	ADVATE	801	00005593095.990	0000000392	000006951427.46	0006575595.77	0000375831.69
XX	00944	2943	10	20093	ADVATE	801	00003795447.000	0000000278	000004849249.39	0004493905.13	0000355344.26
XX	00944	2943	10	20094	ADVATE	801	00004464641.000	0000000348	000005461273.34	0005154907.91	0000306365.43
XX	00944	2944	10	20091	ADVATE	1,2	00003970478.000	0000000227	000004817387.50	0004549202.11	0000268185.39
XX	00944	2944	10	20092	ADVATE	1,2	00006139151.600	0000000328	000007261865.89	0006796938.49	0000464927.40
XX	00944	2944	10	20093	ADVATE	1,2	00004500346.000	0000000226	000005551440.65	0005204872.31	0000346568.34
XX	00944	2944	10	20094	ADVATE	1,2	00005593949.000	0000000284	000006631902.54	0006142986.39	0000488916.15
XX	00944	2945	10	20091	ADVATE	1,8	00009250978.230	0000000318	000010926184.59	0010405099.65	0000521084.94
XX	00944	2945	10	20092	ADVATE	1,8	00012240037.000	0000000411	000013830712.74	0012796292.51	0001034420.23
XX	00944	2945	10	20093	ADVATE	1,8	00007940492.000	0000000310	000009812005.51	0008425714.62	0001386290.89
XX	00944	2945	10	20094	ADVATE	1,8	00009575635.000	0000000306	000010946057.24	0009476623.66	0001469433.58
XX	00944	2946	10	20091	ADVATE	2,4	00011725280.000	0000000309	000013460172.36	0012764830.87	0000695341.49
XX	00944	2946	10	20092	ADVATE	2,4	00014308934.000	0000000388	000017135674.79	0016026920.64	0001108754.15
XX	00944	2946	10	20093	ADVATE	2,4	00012021529.000	0000000361	000014565393.85	0013626020.46	0000939373.39
XX	00944	2946	10	20094	ADVATE	2,4	00014425550.623	0000000395	000017368323.55	0016129979.43	0001238344.12